Dry Eye Disease

The FDA has cleared an investigational new drug application for A197, which is being evaluated for the treatment of dry eye disease, according to a press release from Aramis Biosciences.

An exploration of the expanding roster of dry eye disease therapies and a video perspective detailing corneal cross-linking led coverage from the American Academy of Ophthalmology meeting in New Orleans.

Integrated data from the phase 2 ONSET-1 and phase 3 ONSET-2 clinical trials showed that OC-01 nasal spray effectively improves endogenous basal tear production in a heterogeneous dry eye disease population.

ST-100, a novel dry eye treatment, achieved positive topline results in a phase 2 clinical trial, according to a press release from Stuart Therapeutics.

An FDA clearance and dry eye disease trials led cornea coverage from December.

The top 2021 blogs from Healio/OSN contributors included strategies for dealing with unhappy patients and the possible next steps for Beovu.

The most-read FDA approval stories of 2021 include Tyrvaya nasal spray and Byooviz, the first ophthalmology biosimilar to receive FDA approval.

Reproxalap did not meet the primary endpoint of ocular redness but achieved statistical significance in the secondary endpoint of Schirmer test in a phase 3 clinical trial, according to a press release from Aldeyra Therapeutics.

The TearCare system has received 510(k) clearance from the FDA for the treatment of meibomian gland dysfunction, according to a press release from Sight Sciences.

With the exception of the eventual, however begrudging, acceptance of dry eye disease as a thing, the biggest paradigm shift in the dry eye world has been the acknowledgement that both tear quality and quantity matter.